Liang Schweizer is the Founder, Chairperson and Chief Executive Officer of HiFiBiO Therapeutics. She has over 30 years of research and industry experience with numerous publications and global keynote presentations. She is the co-inventor of 12 immuno-modulatory therapeutic antibodies with over 50 patent publications. She also has contributed to 4 marketed drugs and over 20 clinical candidates.

Previously, Liang co-founded Harbour Biomed and served as its CSO, successfully transforming a technology platform company to an antibody drug discovery enterprise. Before launching her entrepreneurial career, Liang served as Head of Asian Cancer Research at Sanofi, advancing Sanofi’s Asia-Pacific oncology pipeline as well as contributing to global oncology programs from preclinical to clinical efforts. Before joining Sanofi, she was a director at Bristol-Myers Squibb Company.

Liang received a B.S. from the University of Science and Technology of China (USTC) and an M.S. in Microbial Engineering and Chemical Engineering from the University of Minnesota. She earned her Ph.D. in Molecular Biology from the University in Zurich. Her postdoctoral training was with Dr. Harold Varmus, a Nobel Laureate, at Memorial Sloan Kettering Cancer Center (MSKCC).

Francisco Adrian is the Chief Scientific Officer at HiFiBiO Therapeutics. He is an accomplished scientist with more than 20 years of experience in drug discovery and pharmaceutical research and development.

Previously, Francisco worked as a Director at the Sanofi Oncology Division, where he led the research efforts for different small molecule and antibody programs in preclinical and clinical development stages. Before joining Sanofi, he was a Group Leader at the Genomics Institute of the Novartis Research Foundation focused on the discovery of novel kinase inhibitors for Oncology indications.

Francisco received a B.S. and Ph.D. in Molecular Microbiology from the University of Zaragoza, Spain. His postdoctoral training was in Hemato-Immunology at the St Louis Hospital in Paris.

Robert Andtbacka is the Chief Medical Officer at HiFiBiO Therapeutics, bringing over 20 years of experience in clinical research and drug development. He is a renowned clinician scientist and tenured professor of surgical oncology, with a focus on melanoma, oncolytic immunotherapy, and Toll-like Receptor agonists. With more than 80 peer-reviewed articles, 150 abstracts, and 4 book chapters, Robert is a globally recognized expert in his field.

Previously, as the Chief Medical Officer at Seven and Eight Biopharmaceuticals, Robert led the clinical development of innovative intravenously delivered dual agonists for Toll-like Receptor 7 and 8 (TLR 7/8), TLR 7/8-antibody drug conjugates, and oncolytic viruses. His leadership resulted in the acquisition of groundbreaking TLR7/8 assets by Eikon Therapeutics.

Before joining Seven and Eight Biopharma, Robert served as Co-Director of the Melanoma and Cutaneous Oncology Program and Director of the Melanoma Clinical Research Program at the Huntsman Cancer Institute. He established a comprehensive surgical and clinical research program, conducting over 50 clinical trials and leading the OPTiM Phase III trial that led to FDA and EMA approval of talimogene laherparepvec (T-VEC), the first oncolytic virus in its class. He was also the Chief Medical Officer for Vestan Medical Imaging, where he led preclinical and clinical development.

Robert obtained his B.Sc. (Honors) in Biochemistry from McGill University, followed by medical training and a residency in General Surgery. He completed a fellowship in Surgical Oncology at the University of Texas MD Anderson Cancer Center. He is a board-certified surgeon, a Fellow of the American College of Surgeons (FACS), and a Fellow of the Royal College of Surgeons of Canada (FRCSC).

Lynn Bodarky is the Senior Vice President, Global Head of Business Development and Operations at HiFiBiO Therapeutics. She has over 25 years of leadership experience in the global bio-pharma industry spanning corporate strategy, international business development, and finance.

Prior to joining HiFiBiO, Lynn was Vice President, Business Development at Geron where she was responsible for business development including in-licensing, out-licensing, and strategic transaction opportunities. Previously, she was President of LMB Consulting LLC where she provided corporate strategy and end-to-end business development advisory services to biopharmaceutical companies. In her prior executive roles at Intrexon Corporation, Pfizer Inc., Progenics Pharmaceuticals and Merck & Co., Inc. Lynn negotiated and structured corporate and public-private partnerships.

Lynn has a B.S. from The Wharton School, University of Pennsylvania and an M.B.A. from Columbia Business School, Columbia University.

John Pallante is the Vice President, Global Head of Clinical Operations at HiFiBiO Therapeutics. He has over 15 years of clinical operations experience preparing and executing global clinical trials alongside partners and collaborators.

Prior to HiFiBiO, John served as the Global Head of Clinical Quality Management and Training at Novartis Institutes for BioMedical Research. Before then, he held various leadership roles at Novartis in the areas of Governance and Operational Excellence, Clinical Operations, and Clinical Trial Intelligence.

John received a B.S. from Rutgers University and an M.S. in Quality Assurance/Regulatory Affairs from Temple University.

Christos Hatzis is the Vice President, Global Head of Translational Medicine at HiFiBiO Therapeutics. He is an engineer by training with extensive translational and immune-oncology experience and an entrepreneurial mindset.

Prior to HiFiBiO, Christos was a Director, Tumor Strategy Lead, Translational Medicine at Bristol-Myers Squibb where he provided scientific and strategic leadership for the solid tumor programs. Before BMS, he served as an Associate Professor for the Department of Internal Medicine (Medical Oncology) at Yale University School of Medicine, where he still holds an Adjunct faculty position. Earlier in his career, he co-launched two start-up companies, Silico Insights and Nuvera Biosciences, an informatics and data mining company and ventured-funded spin off the MDACC respectively.

Christos received a B.S. from the University of Patras and a Ph.D. from the University of Minnesota.

Jinping Gan is the Vice President, Global Head of Research at HiFiBIO Therapeutics. He is a biological chemist with 20 years of biopharma industry experience. Jinping has strong experience in drug discovery and development including drug metabolism, PK/PD, and chemical toxicology.

Previously, Jinping worked at Bristol-Myers Squibb, focusing on preclinical optimization and characterization of diverse pipeline molecules from early discovery to NDA filings.

Jinping received a B.S. from University of Science & Technology of China and a Ph.D. in Biological Chemistry from MIT.

Alexandre Grassin is the Vice President of Finance at HiFiBiO Therapeutics. He has over 20 years of experience in financial operations and management, including deal operations, business planning, and global accounting.

Prior to joining HiFiBiO Therapeutics, Mr. Grassin served as Consulting CFO at Danforth Advisors and as Chief Financial Officer for Aleva Neurotherapeutics where he supported the transition of the company from R&D to commercialization.

Before Aleva, Mr. Grassin served as Chief Financial Officer at Genkyotex, a Swiss biotech company listed on Euronext Paris and Brussels, managing all finance and administrative activities of three entities in France and Switzerland. Mr. Grassin played a key role in the Reverse Take Over (RTO) process through which Genkyotex became public in 2017 and in the strategic merger with Calliditas Therapeutics in 2020/2021.

Previously, Mr. Grassin served in various senior financial roles at Alexion Pharmaceuticals and Novartis and worked as an auditor at KPMG.

Edward Rocnik is the Executive Director, Global Head of CMC at HiFiBiO Therapeutics. He is a seasoned scientist with 20 years of experience in CMC and research.

Previously, Ed has held various CMC and research roles at Takeda, Millennium, and Organogenesis. Most recently, he served as Director, Head of Late-Stage Analytical Development, Cell Therapies at Takeda.

Ed received a B.S. and Ph.D. from Western University.

Steven Chen is the General Counsel at HiFiBiO Therapeutics and leads all legal activities in the company including corporate compliance, IP, and contracting.

Prior to joining, Steve served as the Sr. Patent Attorney at DSM Nutritional Products LLC. At DSM, he helped build a global IP portfolio and secured strategic partnerships for some of the company’s most important products. Before DSM, he spent 5 years at Jones Day LLP, a private legal practice, providing legal services to a broad range of biotechnology and pharmaceutical companies. Prior to entering law school, Steve conducted bioinformatic research at Vertex Pharmaceuticals.

Steve received a B.S. from Fudan University, a Ph.D. in Molecular and Cell Biology from the University of Maryland, and holds a J.D. from Fordham University School of Law.

Roshan Kumar is the Senior Director, US External Innovation at HiFiBiO Therapeutics. He is a scientist with over 15 years of experience in the study of complex biological systems. Roshan leads US External Innovation activities to identify high impact partnerships and collaborations for the company’s internal pipeline and DIS® platform.

Roshan's previous research was focused on the study of transcriptional regulatory networks in mammalian systems, and on understanding how cellular heterogeneity influences fate decisions in individual pluripotent stem cells.

Roshan received a B.S. from the California Institute of Technology and Ph.D. in Biochemistry from the Scripps Research Institute. His postdoctoral studies were performed at the Whitehead Institute for Biological Research at MIT and the Wyss Institute for Biologically Inspired Engineering at Harvard Medical School.

Yun-Yueh Lu is the Senior Director, Discovery Biology and In Vivo Pharmacology at HiFiBiO Therapeutics. She is a biologist with seven years of industry experience in early drug discovery. Yun-Yueh leads the in-vivo team and contributes to the company’s internal pipelines from target nomination and drug discovery through IND submissions.

Prior to joining HiFiBiO, Yun-Yueh worked at Sanofi in Hepatitis B virus research and anti-viral drug screening.

Yun-Yueh received a B.S. from National Chung-Hsing University, an M.S. from the Wageningen University & Research and a Ph.D. in Infection Biology from University of Basel.

Qian Zhang is the Senior Director, Global Head of Antibody Discovery and Optimization at HiFiBiO Therapeutics. He is a biochemist by training with 10 years of industry experience and expertise in structural biology, analytical chemistry and antibody engineering.

Before joining HiFiBiO, Qian worked at Regeneron as a Staff Scientist focusing on novel protein biochemistry and mass spectrometry-based methods for antibody characterization, supporting various mono and bi-specific antibody and ADC programs.

Qian holds a B.S. from the University of Science & Technology of China, a M.S. in Biochemistry from Georgia Institute of Technology, and a Ph.D. in Analytical Chemistry from Florida State University/National High Magnetic Field Laboratory. His postdoctoral training was focused on biomarkers and bioanalysis at Merck Research Laboratories.

Pascaline Mary is the Senior Director, Head of Single Cell Science at HiFiBiO Therapeutics leading a unique single-cell platform to develop novel applications for accelerated drug discovery and development. She is a scientific leader with extensive experience in single-cell based technologies.

Previously, Pascaline worked as the director of assay development at Pattern Bioscience, a biotech developing a diagnostic platform that delivers rapid pathogen identification and antibiotic susceptibility test. Prior to Pattern, Pascaline worked at GnuBIO (acquired by Bio-Rad), where she contributed to the development of a microfluidic-based next generation DNA sequencer.

Pascaline holds a M.S. in Physics from the Ecole Normale Superieure in Paris and received a Ph.D. from the Ecole Superieure de Physique et Chimie Industrielles (ESPCI). She received her postdoctoral fellow training at Harvard University with one of HiFiBiO founders, David Weitz.

Vincent Tse is the Senior Director of Staff and Strategy at HiFiBiO Therapeutics. His professional experience includes R&D Product Development, Business Development, and Strategy Consulting for both small biotech and large pharma.

Vincent previously worked for Genentech, conducting competitive intelligence for the company’s asthma portfolio. Prior to Genentech, he performed Product and Business Development for Armata Pharmaceuticals, an innovative biotech focused on therapeutics against antibiotic-resistant infections. Most recently, he was a strategy and portfolio analysis consultant for IQVIA with diverse engagements in digital therapeutics, rare disease, and oncology.

Vincent holds a B.S. from UCLA, an M.S. in Regulatory Affairs from Northeastern University, and an MBA from Duke University Fuqua School of Business.

Sami Ellouze is the Managing Director, France, at HiFiBiO Therapeutics. He is an engineer and scientist with over 7 years of experience working with and optimizing single cell technologies for both internal drug discovery programs and external partnerships.

Previously, Sami was involved in NGS data analysis and biomarker identification for a novel metabolomics approach. Sami holds an engineering degree in Conception and Innovation of Bioproducts from the University of Technology of Compiègnem.

Stephen Beauparlant is the Director of Global Scientific Operations at HiFiBiO Therapeutics. He is an accomplished operations manager with almost 10 years of experience in laboratory operations and standardization.

Before joining HiFiBiO, Steve was the Director of Laboratory Operations for Bioinnovation Labs (BioLabs), a biotech coworking space for early-stage companies. There, he developed lab operations protocols, safety programs and managed day-to-day lab operations at three Massachusetts locations housing over 50 early-stage biotech companies. He also built out new locations and lead efforts in multiple site relocations in the Boston area. Steve developed network-wide initiatives in systems operations and aided in the buildout and setup of multiple international locations including Paris, France and Heidelberg, Germany.

Steve received a B.S. from Pennsylvania State University and a Ph.D. in Molecular Biology and Genetics from Temple University, in Pennsylvania. His post-doctoral training was at the Molecular Oncology Research Institute at Tufts Medical Center in Boston, MA.

Chao Kong is the Director of China External Innovation at HiFiBiO Therapeutics and carries extensive knowledge and working experience in antibody drug R&D.

Previously, Chao Kong worked for SanyouBio Pharmaceuticals for over five years, providing multiple services from antibody discovery to IND enabling studies. He is experienced in pre-clinical target validation, antibody discovery biology, and project management. In addition, he holds a strong background in target biology and cancer immunotherapy.

Chao Kong received a master’s degree from Shanghai University & Shanghai Pasteur Institute of the Chinese Academy of Sciences in China, majoring in Microbiology and Molecular Immunology.

Melissa Harney is the Director of Clinical Operations at HiFiBiO Therapeutics. She is a clinical operations professional with over 25 years of clinical trial experience in strategic clinical operations support for Phase I-III global trials, vendor management, and strategic partnerships.

Prior to joining HiFiBiO Therapeutics, Melissa served as Director, Clinical Operations at Seven and Eight Biopharmaceuticals, where she led the Clinical Operations team of innovative intravenously delivered dual agonists for Toll-like Receptor 7 and 8 (TLR 7/8).

Melissa worked in large pharmaceutical companies such as Johnson & Johnson, Pharmacia and SmithKline Beecham as well as smaller Biotech companies including Advaxis, MedPointe and Seven and Eight Biopharmaceuticals.

She received a B.S. from Capella University.